Marizyme, Inc. MRZM

MRZM Company Overview

Marizyme, Inc. (NASDAQ: MRZM) is a biotechnology and medical technology company focused on cardiovascular, surgical, and life-science applications. The company has concentrated its operations on commercializing and developing products intended to improve surgical outcomes, vascular health, and enzyme-based therapeutic technologies. Public filings and investor materials identify the company’s principal focus areas as vascular and cardiac surgery support products and marine-derived enzyme technologies.

The company’s primary commercial asset has been DuraGraft, a vascular graft preservation solution designed to reduce graft damage during coronary artery bypass graft (CABG) procedures and other vascular surgeries. Marizyme has also pursued development of Krillase, a proteolytic enzyme technology derived from marine sources that has been explored for potential therapeutic and industrial applications. The company evolved through a series of restructurings, acquisitions, and strategic pivots, transitioning from earlier biotechnology activities toward cardiovascular and surgical product commercialization. Public disclosures indicate that management has emphasized asset monetization, licensing opportunities, and strategic partnerships as part of its long-term strategy.